The fate of Belgian biopharma Oxurion (Euronext Brussels: OXUR) has been sealed.
Oxurion announced Monday that top-line data in its KALAHARI Phase II, Part B trial for diabetic macular edema (DME) failed to show that its novel PKal inhibitor, THR-149, improved vision as much as the comparator aflibercept, at month three, the study’s primary endpoint.
Aflibercept is the anti-VEGF therapy marketed by Regeneron (Nasdaq: REGN) and Bayer (BAYN: DE) under the brand name Eylea.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze